Work

Phase 2 peri-operative study of fianlimab + cemiplimab + chemotherapy versus cemiplimab + chemotherapy in resectable early-stage non-small cell lung cancer (NSCLC).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps8117

Authors: Ekaterine Arkania, Tamta Makharadze, Gopal Kunta, Tamar Melkadze, Ana Baramidze, Alexander I. Spira, Luis G. Paz-Ares, Nicolas Girard, Ji Sun Park, Maria Ghattas, Yuntong Li, Siyu Li, Mark Salvati, Israel Lowy, Matthew G. Fury, Luca Paoluzzi

Institutions: Universidad Complutense de Madrid, Regeneron (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Regeneron Pharmaceuticals

OpenAlex ID: W4410816831

Cites:

Cited by:

Related to: 10